Lymphoma Clinical Trials

Official title: Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

DLBCL - Diffuse Large B Cell Lymphoma · University Health Network, Toronto

Comparing Zilovertamab vedotin with Vincristine for diffuse large b-cell lymphoma

Explore this study →

Sites in Edmonton, Halifax and 3 more cities

Official title: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B-Cell Lymphoma · Merck Sharp & Dohme LLC

Comparing KITE-753 with Axicabtagene Ciloleucel for relapsed or refractory large b-cell lymphoma

Explore this study →

Sites in Montreal and Québec

Official title: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Relapsed or Refractory Large B-cell Lymphoma · Kite, A Gilead Company

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for lymphoma.

Comparing CPA with DPX-Survivac for relapsed diffuse large b-cell lymphoma

Explore this study →

One site, in Saskatoon

Official title: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed Diffuse Large B-cell Lymphoma · ImmunoVaccine Technologies, Inc. (IMV Inc.)

Comparing Bleomycin with Brentuximab vedotin for Hodgkin lymphoma

Explore this study →

Sites in Halifax, Hamilton and 5 more cities

Official title: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Hodgkin Lymphoma · University College, London

Comparing Odronextamab with Rituximab for follicular lymphoma (FL)

Explore this study →

Sites in Calgary, Greenfield Park and 3 more cities

Official title: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma (FL) · Regeneron Pharmaceuticals

Comparing 5 approaches for b-cell non-hodgkin lymphoma

Explore this study →

One site, in Montreal

Official title: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

B-cell Non-Hodgkin Lymphoma · Iksuda Therapeutics Ltd.

Comparing Golcadomide with Lenalidomide for follicular lymphoma

Explore this study →

Sites in Sherbrooke, Québec and 2 more cities

Official title: A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Follicular Lymphoma · Celgene

Testing Surovatamig for b-cell non-hodgkin lymphoma

Explore this study →

Sites in Barrie, Brampton and 2 more cities

Official title: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

B-cell Non-Hodgkin Lymphoma · AstraZeneca

Testing zamtocabtagene autoleucel with Cyclophosphamide for refractory diffuse large b cell lymphoma (DLBCL)

Explore this study →

Sites in Edmonton and Toronto

Official title: DALY II USA/ MB-CART2019.1 for DLBCL

Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Miltenyi Biomedicine GmbH

Comparing 5 approaches for peripheral t cell lymphoma

Explore this study →

Sites in Ottawa and Toronto

Official title: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Peripheral T Cell Lymphoma · Acrotech Biopharma Inc.

Comparing 3 approaches for large b-cell lymphoma

Explore this study →

Sites in Calgary, Hamilton and 2 more cities

Official title: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

Large B-cell Lymphoma · AstraZeneca

Testing Obinutuzumab with Glofitamab for b-cell non-hodgkins lymphoma

Explore this study →

Sites in Calgary and Winnipeg

Official title: A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkins Lymphoma · Hoffmann-La Roche

Comparing 4 approaches for relapsed/refractory (r/r) mature b cell non Hodgkin

Explore this study →

Sites in Calgary, Montreal and 1 more city

Official title: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) · Arvinas Inc.

Testing glofitamab for diffuse large b cell lymphoma (DLBCL)

Explore this study →

Sites in Toronto and Montreal

Official title: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Diffuse Large B Cell Lymphoma (DLBCL) · University Health Network, Toronto

Testing Pembrolizumab with Bendamustine Hydrochloride for classical Hodgkin lymphoma

Explore this study →

One site, in Toronto

Official title: Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Classical Hodgkin Lymphoma · University Health Network, Toronto

Comparing Gemcitabine with Brentuximab vedotin for Hodgkin lymphoma

Explore this study →

Sites in Montreal, Calgary and 9 more cities

Official title: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma · Canadian Cancer Trials Group

Comparing Soquelitinib with Belinostat for not otherwise specified peripheral t-cell lymphoma

Explore this study →

Sites in Ottawa, Toronto and 1 more city

Official title: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise Specified · Corvus Pharmaceuticals, Inc.

Testing Zanubrutinib with Sonrotoclax for mantle cell lymphoma

Explore this study →

Sites in Edmonton, Toronto and 1 more city

Official title: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Mantle Cell Lymphoma · Canadian Cancer Trials Group

Testing Methotrexate with Rituximab (where available) for non-hodgkin lymphoma

Explore this study →

Sites in Calgary, Hamilton and 6 more cities

Official title: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Non-hodgkin Lymphoma · Canadian Cancer Trials Group

Testing TBI-2001 with Cyclophosphamide for relapsed or refractory CD19+ b-cell lymphoma

Explore this study →

One site, in Toronto

Official title: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory CD19+ B-cell Lymphoma · University Health Network, Toronto

Comparing 3 approaches for non-hodgkin lymphoma

Explore this study →

Sites in Montreal, Toronto and 1 more city

Official title: A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Lymphoma, Non-Hodgkin · Eli Lilly and Company

Comparing 3 approaches for untreated follicular lymphoma

Explore this study →

Sites in Barrie, Chicoutimi and 8 more cities

Official title: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Untreated Follicular Lymphoma · AstraZeneca

Comparing 3 approaches for large b-cell lymphoma

Explore this study →

One site, in Toronto

Official title: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

Large B-cell Lymphoma · University Health Network, Toronto

Comparing Obinutuzumab with Rituximab for lymphoma

Explore this study →

Sites in London, Ottawa and 1 more city

Official title: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma · Hoffmann-La Roche

Comparing TLN-121 with zeprumetostat for lymphoma

Explore this study →

One site, in Vancouver

Official title: TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Lymphoma · Treeline Biosciences, Inc.

Comparing cemacabtagene ansegedleucel with Foresight CLARITY™ IUO MRD test, for large b-cell lymphoma

Explore this study →

Sites in Montreal, Calgary and 3 more cities

Official title: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Large B-cell Lymphoma · Allogene Therapeutics

Comparing 3 approaches for relapsed and/or refractory b-cell lymphoma

Explore this study →

2 sites in Montreal

Official title: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Relapsed and/or Refractory B-cell Lymphoma · Kite, A Gilead Company

Comparing 14 approaches for non-hodgkin lymphoma

Explore this study →

Sites in Edmonton, Kelowna and 8 more cities